Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- UOA2-2325
- Type
- D - Journal article
- DOI
-
10.1016/s1470-2045(18)30687-9
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 57
- Volume
- 20
- Issue
- 1
- ISSN
- 1470-2045
- Open access status
- Compliant
- Month of publication
- December
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
21
- Research group(s)
-
-
- Citation count
- 97
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Contribution A: Contribution to the organisation of the conduct of the study,Contribution to analysis and interpretation of the study data
Contribution B: The author helped draft the output,Critique the output for important intellectual content
- Non-English
- No
- English abstract
- -
